No Drug
No Drug is an intervention with 38 clinical trials. Currently 4 active trials ongoing. Historical success rate of 89.3%.
Success Metrics
Based on 25 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
2
Mid Stage
4
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
89.3%
25 of 28 finished
10.7%
3 ended early
4
trials recruiting
38
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)
Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy
Treatment of Orthostatic Intolerance
Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i
Clinical Trials (38)
A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)
Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
Immune System Effects in Children Born to Women With Multiple Sclerosis Treated With Monoclonal Antibody Therapy During Pregnancy
Treatment of Orthostatic Intolerance
Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i
A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments
Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China
Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan
Comparison of Indirect Calorimetry by Q-NRG With Deltatrac II
Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers
Study of Psychiatric Aspects in Women With Lower Urinary Tract Symptoms
Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)
Tracking and Exploring the Source of Viral REbound
Project Affinity: Excess Cancer Blood Testing
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 38